Christopher H Goss1, Stephanie J MacNeill2, Hebe B Quinton3, Bruce C Marshall4, Alexander Elbert4, Emily A Knapp4, Kristofer Petren4, Elaine Gunn5, Joanne Osmond5, Diana Bilton6. 1. Department of Medicine, University of Washington, Seattle, Washington, USA. 2. Department of Occupational and Environmental Medicine, Imperial College London, London, UK. 3. Value Reporting and Analytics, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, USA. 4. Cystic Fibrosis Foundation, Bethesda, Maryland, USA. 5. UK Cystic Fibrosis Trust, London, UK. 6. Department of Respiratory Medicine, Royal Brompton Hospital, London, UK.
Abstract
BACKGROUND: People with cystic fibrosis (CF) are managed differently in the USA and UK providing an opportunity to learn from differences in practice patterns. OBJECTIVES: To compare cross-sectional demographics, practice patterns and clinical outcomes between US and UK CF patients. METHODS: This was a cross-sectional study using 2010 data from patients in the US Cystic Fibrosis Foundation and the UK Cystic Fibrosis patient registries. The a priori outcome measures of interest were lung function and nutritional status. Descriptive statistics and two sample comparisons were performed. Stratification and multivariable linear regression were used to adjust for confounding. RESULTS: The study cohort included 13 777 children and 11 058 adults from the USA and 3968 children and 3965 adults from the UK. In children, mean body mass index centiles were similar. Lung function (FEV1 and FVC% predicted) was significantly higher in US patients ages 6-25 years of age. In a regression model adjusted for only age, FEV1% predicted was on average 3.31% of predicted (95% CI 2.65 to 3.96) higher in the USA compared with the UK. When adjusted for age, age at diagnosis, gender, pancreatic insufficiency and genotype, FEV1% predicted was on average 3.03% of predicted (95% CI 2.37 to 3.69) higher in the USA compared with the UK These differences persisted despite adjustment for possible confounders. Hypertonic saline and dornase alfa were much more commonly prescribed in US children. CONCLUSIONS: Children and young adults with CF have better lung function in the USA compared with the UK despite similar nutritional status. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND:People with cystic fibrosis (CF) are managed differently in the USA and UK providing an opportunity to learn from differences in practice patterns. OBJECTIVES: To compare cross-sectional demographics, practice patterns and clinical outcomes between US and UK CF patients. METHODS: This was a cross-sectional study using 2010 data from patients in the US Cystic Fibrosis Foundation and the UK Cystic Fibrosispatient registries. The a priori outcome measures of interest were lung function and nutritional status. Descriptive statistics and two sample comparisons were performed. Stratification and multivariable linear regression were used to adjust for confounding. RESULTS: The study cohort included 13 777 children and 11 058 adults from the USA and 3968 children and 3965 adults from the UK. In children, mean body mass index centiles were similar. Lung function (FEV1 and FVC% predicted) was significantly higher in US patients ages 6-25 years of age. In a regression model adjusted for only age, FEV1% predicted was on average 3.31% of predicted (95% CI 2.65 to 3.96) higher in the USA compared with the UK. When adjusted for age, age at diagnosis, gender, pancreatic insufficiency and genotype, FEV1% predicted was on average 3.03% of predicted (95% CI 2.37 to 3.69) higher in the USA compared with the UK These differences persisted despite adjustment for possible confounders. Hypertonic saline and dornase alfa were much more commonly prescribed in US children. CONCLUSIONS:Children and young adults with CF have better lung function in the USA compared with the UK despite similar nutritional status. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Theodore G Liou; Frederick R Adler; Barbara C Cahill; Stacey C FitzSimmons; David Huang; Jonathan R Hibbs; Bruce C Marshall Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: Nicole Mayer-Hamblett; Margaret Rosenfeld; Julia Emerson; Christopher H Goss; Moira L Aitken Journal: Am J Respir Crit Care Med Date: 2002-08-15 Impact factor: 21.405
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Lisa Saiman; Bruce C Marshall; Nicole Mayer-Hamblett; Jane L Burns; Alexandra L Quittner; Debra A Cibene; Sarah Coquillette; Ann Yunker Fieberg; Frank J Accurso; Preston W Campbell Journal: JAMA Date: 2003-10-01 Impact factor: 56.272
Authors: Zhe Hui Hoo; Elizabeth Coates; Chin Maguire; Hannah Cantrill; Nadia Shafi; Edward F Nash; Angela McGowan; Stephen J Bourke; William G Flight; Thomas V Daniels; Julia A Nightingale; Mark I Allenby; Rachael Curley; Martin J Wildman Journal: Eur J Clin Microbiol Infect Dis Date: 2018-08-18 Impact factor: 3.267
Authors: Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush Journal: Nat Rev Dis Primers Date: 2015-05-14 Impact factor: 52.329
Authors: Anne L Stephenson; Jenna Sykes; Sanja Stanojevic; Bradley S Quon; Bruce C Marshall; Kristofer Petren; Josh Ostrenga; Aliza K Fink; Alexander Elbert; Christopher H Goss Journal: Ann Intern Med Date: 2017-03-14 Impact factor: 25.391
Authors: Christopher H Goss; Jenna Sykes; Sanja Stanojevic; Bruce Marshall; Kristofer Petren; Josh Ostrenga; Aliza Fink; Alexander Elbert; Bradley S Quon; Anne L Stephenson Journal: Am J Respir Crit Care Med Date: 2018-03-15 Impact factor: 30.528
Authors: João Paulo Heinzmann-Filho; Leonardo Araujo Pinto; Paulo José Cauduro Marostica; Márcio Vinícius Fagundes Donadio Journal: J Bras Pneumol Date: 2015 Nov-Dec Impact factor: 2.624